Retraction: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells (Carcinogenesis 35 (2203-2213) DOI: 10.1093/carcin/bgu124)

I. Lu Lai, Chih Chien Chou, Po Ting Lai, Chun Sheng Fang, Lawrence A. Shirley, Ribai Yan, Xiaokui Mo, Mark Bloomston, Samuel K. Kulp, Tanios Bekaii-Saab, Ching Shih Chen

Research output: Contribution to journalComment/debate

Abstract

Carcinogenesis is retracting this paper following an institutional investigation conducted by The Ohio State University in response to concerns related to possible image manipulation. Following the institution's review, The Ohio State University determined that the images for Figures 1D, and 5A were intentionally falsified by Dr Ching-Shih Chen. Given the presence of falsified data in these figures, the University has requested that the publication be retracted. Dr Chen formally consented to this retraction during the institutional investigation, and the Journal has more recently received agreement for the retraction from Samuel Kulp, Lawrence Shirley, Mark Bloomston and Tanios Bekaii-Saab. Carcinogenesis has not received responses from the remaining authors and/or has been unable to trace their current affiliations despite numerous attempts. The Journal understands that attempts were made to contact all authors during the institutional investigation.

Original languageEnglish (US)
Pages (from-to)E16
JournalCarcinogenesis
Volume40
Issue number2
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Retraction: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells (Carcinogenesis 35 (2203-2213) DOI: 10.1093/carcin/bgu124)'. Together they form a unique fingerprint.

Cite this